Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
P04626
UPID:
ERBB2_HUMAN
Alternative names:
Metastatic lymph node gene 19 protein; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; Tyrosine kinase-type cell surface receptor HER2; p185erbB2
Alternative UPACC:
P04626; B2RZG3; B4DHN3; Q14256; Q6LDV1; Q9UMK4; X5D2V5
Background:
Receptor tyrosine-protein kinase erbB-2, also known as HER2, plays a pivotal role in the regulation of cell growth and differentiation. It is part of several cell surface receptor complexes and is essential for the neuregulin-receptor complex. HER2's involvement in the stabilization of peripheral microtubules and transcriptional regulation underscores its multifaceted role in cellular processes.
Therapeutic significance:
HER2 is implicated in the pathogenesis of various cancers, including gliomas, ovarian, lung, and gastric cancers. Its overexpression is a hallmark of aggressive tumor phenotypes, making it a critical target for cancer therapy. Understanding the role of HER2 could open doors to potential therapeutic strategies, particularly in the development of targeted therapies for HER2-positive cancers.